公开(公告)号：EP3392245A1

公开(公告)日：2018-10-24

申请号：EP16874860.6

申请日：2016-12-15

申请人： Precedo Pharmaceuticals Co., Ltd.

发明人： LIU, Jing ,  LIU, Qingsong ,  JIANG, Taoshan ,  WANG, Aoli ,  WU, Jiaxin ,  WU, Hong ,  QI, Ziping ,  CHEN, Yongfei ,  ZOU, Fengming ,  WANG, Wenchao ,  ZHAO, Zheng ,  WANG, Li ,  WANG, Beilei

IPC分类号： C07D401/12 ,  C07D239/48 ,  C07D403/12 ,  C07D239/47 ,  C07D409/12 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  A61P35/00 ,  A61P35/02

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K31/551 ,  C07D239/47 ,  C07D239/48 ,  C07D401/12 ,  C07D403/12 ,  C07D409/12 ,  Y02P20/55

摘要： The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.